Share on StockTwits

Shares of InterMune (NASDAQ:ITMN) reached a new 52-week high during trading on Thursday , AnalystRatings.Net reports. The company traded as high as $41.24 and last traded at $41.20, with a volume of 851,185 shares traded. The stock had previously closed at $39.96.

Several analysts have recently commented on the stock. Analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Separately, analysts at ING Group upgraded shares of InterMune from a “market perform” rating to a “buy” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Finally, analysts at Leerink Swann upgraded shares of InterMune from a “market perform” rating to an “outperform” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $39.08.

The stock has a 50-day moving average of $35.12 and a 200-day moving average of $24.25. The company’s market cap is $4.041 billion.

InterMune (NASDAQ:ITMN) last announced its earnings results on Thursday, May 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the previous year, the company posted ($0.64) earnings per share. The company’s revenue for the quarter was up 188.6% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.34 earnings per share for the current fiscal year.

In other InterMune news, CEO Daniel G. Welch unloaded 4,565 shares of InterMune stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $40.06, for a total value of $182,873.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.